Tumor mutational burden (TMB), a biomarker used to assess whether a patient will respond to immunotherapy, needs to be recalculated in order to be useful for patients of Asian or African descent. Scientists at the Dana-Farber Cancer Institute found a significant bias in the estimated TMB values affecting these populations and adjusted them for those patients. Read More

Two new studies now have uncovered fungal DNA in tumors throughout the body and endeavor to characterize the cancer mycobiome. Both studies were published in the Sept. 29, 2022, online issue of Cell. Although the association between cancer and individual microbes has long been explored, recent attention has focused on the whole human microbiome. Read More

Researchers from Sensei Biotherapeutics Inc. have presented preclinical data on SNS-101. Read More

Researchers from University Hospital and University of Zürich aimed to assess the effects of serotonin on the tumor microenvironment. Read More

Prometheus Biosciences Inc. has received FDA clearance of its IND application to proceed with a phase I trial of PRA-052 for ulcerative colitis. Read More

Incyte Corp. has entered into an agreement to acquire Villaris Therapeutics Inc., a company developing antibody therapeutics for vitiligo. Read More

Oncternal Therapeutics Inc. has received IND clearance from the FDA for a phase I/II study of ONCT-808. Read More

Leucine-rich repeat kinase 2 (LRRK2) mutations adversely impair multiple physiological processes, and gain-of-function mutations in the LRRK2 gene are common in familial forms of Parkinson’s disease (PD). Read More

Beta Pharma Inc. has patented pyridopyrimidines acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer. Read More

Biomedcode Hellas SA has synthesized carboxamide derivatives reported to be useful for the treatment of inflammatory disorders. Read More

Imunon Inc. has reported partial results from an ongoing nonhuman primate study designed to examine the immunogenicity of its proprietary Placcine vaccine (PL-COV). The data support Placcine as a viable alternative to mRNA vaccines. Read More

Infex Therapeutics Ltd. has divulged nonstructural protein 3 (nsp3, PL-PRO) macrodomain (Mac1) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome. Read More

Bionanosim Ltd. has discovered cannabinoid CB1 receptor antagonists reported to be useful for the treatment of metabolic disorders. Read More

For a long time, α2-adrenoceptor antagonists have been successfully used as adjunct therapy to improve pharmacotherapy of antipsychotics, antidepressants or anti-parkinsonian drugs. Read More

Tohoku University has divulged quinoline compounds acting as histamine N-methyltransferase (HNMT) inhibitors reported to be useful for the treatment of narcolepsy, Alzheimer's disease and attention deficit hyperactivity disorder (ADHD). Read More

Additional early-stage research and drug discovery news in brief, from: Applied DNA Sciences, Cardiol Therapeutics, SQZ Biotechnologies, Therapeutic Solutions International. Read More